Abstract
The clinicopathologic features of DNA methyltransferase 3A (DNMT3A)-mutated de novo acute myeloid leukemia (AML), and the significance of variant type, variant allele frequency (VAF), and multiple concomitant DNMT3A mutations, remain poorly defined. We examined 104 DNMT3A-mutated de novo AML patients from 2 major centers. Most (82%) had normal karyotype (NK); R882H variants were frequent(38%). The most commonly comutated genes included nucleophosmin (NPM1; 53%), Fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (25%), IDH1 (23%), IDH2 (23%), and TET2 (21%). Patients with high DNMT3A VAF at diagnosis (≥44%; DNMT3AHIGH) had more significant leukocytosis and higher blast counts in peripheral blood and bone marrow. DNMT3AHIGH cases were associated with much shorter event-free survival (EFS; 14.1 vs 56.8 months) and overall survival (OS; 18.3 months vs not reached) compared with cases of patients with low DNMT3A (DNMT3ALOW). Thirteen patients had 2 DNMT3A variants and similar VAFs at diagnosis that tracked together at multiple time points after chemotherapy and/or stem cell transplantation (SCT). In multivariable analyses performed in NK patients who received standard induction chemotherapy, presence of 2 DNMT3A mutat...Continue Reading
References
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholMichael Heuser
Feb 1, 2012·Leukemia·A RennevilleC Preudhomme
Apr 12, 2012·Blood·Ana Flávia Tibúrcio RibeiroRuud Delwel
May 9, 2012·Nature Genetics·Cathy C LaurieBruce S Weir
May 2, 2013·Blood·Verena I GaidzikKonstanze Döhner
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Feb 14, 2014·Nature·Liran I ShlushJohn E Dick
Oct 2, 2014·Blood·Richard F SchlenkUNKNOWN German-Austrian AML Study Group
Oct 5, 2014·Journal of Hematology & Oncology·Sanam LoghaviJoseph D Khoury
Nov 6, 2014·British Journal of Haematology·Gro G PløenAnni Aggerholm
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Jan 1, 2015·Blood·R Coleman LindsleyBenjamin L Ebert
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Sep 15, 2016·Leukemia Research·Yanjun SunYang Xu
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Jan 13, 2018·Haematologica·Olga K WeinbergRobert P Hasserjian
May 5, 2018·Blood·Sanjay S PatelOlga K Weinberg
Jul 11, 2018·Nature·Sagi AbelsonLiran I Shlush
May 31, 2019·American Journal of Hematology·Jennifer B DunlapElie Traer
Jun 15, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Martin S TallmanNdiya Ogba
Jul 2, 2019·Trends in Immunology·Laurent Yvan-Charvet, Lai Guan Ng
Jul 12, 2019·Journal of Translational Medicine·Xiao-Qing YuanXiao-Ping Chen
Feb 1, 2020·British Journal of Haematology·David C LinchRosemary E Gale
May 29, 2020·Leukemia·Ann-Kathrin EisfeldClara D Bloomfield